Phase 1/2Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)
- Sponsor
- Dizal Pharmaceuticals (Industry)
- Enrollment
- 220 planned
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- DZD6008; Sunvozertinib; Osimertinib
- Ages
- adults, older adults
- Registry
- NCT07079475
Full record on ClinicalTrials.gov
From the registry
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment
Primary outcomes
- Part A: To assess safety and tolerability
- Part B: To assess anti-tumor activity
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered